Abstract Number: 1440 • ACR Convergence 2021
Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
Background/Purpose: Sjӧgren’s syndrome (SS) is a systemic autoimmune disease that is associated with a lymphoma risk 14-fold that of the general population. Greater focal lymphocytic…Abstract Number: 0300 • ACR Convergence 2021
Salivary Gland Epithelial Cells Transcriptomic Analysis Highlight Their Potential Involvement in Extracellular Matrix Modification in Sjögren’s Syndrome
Background/Purpose: Salivary gland epithelial cells (SGECs) participate to the hyper activation of the immune system in primary Sjögren’s syndrome (pSS). This study aimed to analyze…Abstract Number: 0316 • ACR Convergence 2021
Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials
Background/Purpose: Sjögren’s is a chronic autoimmune disease symptomatically characterized by dryness, pain and fatigue, which are typically assessed in clinical trials using EULAR Sjögren’s Syndrome…Abstract Number: 1464 • ACR Convergence 2021
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Background/Purpose: Congenital Heart Block (CHB) complicates 2% of anti-Ro/SSA antibody positive pregnancies and carries substantial perinatal morbidity and mortality. Almost all survivors require lifelong pacing.…Abstract Number: 0301 • ACR Convergence 2021
Activation of Akt Signaling Pathway in the Minor Salivary Glands of Patients with Primary Sjögren’s Syndrome Does Not Relate with Clinical Phenotype
Background/Purpose: Akt is a phosphoinositide-dependent serine/threonine kinase with diverse regulatory functions that has been implicated in numerous pathological processes, including oncogenesis and autoimmune diseases. Indirect…Abstract Number: 0317 • ACR Convergence 2021
Patient and Physician Perspectives on EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): A Qualitative Interview Study
Background/Purpose: The aim of this research was to gain qualitative patient and physician feedback on the EULAR Sjögren’s syndrome patient reported index (ESSPRI) and the…Abstract Number: 1636 • ACR Convergence 2021
Pediatric Rheumatologists’ Perspectives on Diagnosis, Treatment and Outcomes of Sjögren Syndrome in Children and Adolescents
Background/Purpose: Sjögren syndrome in children and adolescents often presents differently from adult disease, with many pediatric patients failing to meet adult criteria. Additionally, treatment and…Abstract Number: 0302 • ACR Convergence 2021
Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic autoimmune disease primarily involving the exocrine glands where the involvement of the innate immune system is largely uncharacterized.…Abstract Number: 0318 • ACR Convergence 2021
Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity
Background/Purpose: Since primary Sjögren’s Syndrome (pSS) is a very heterogeneous disease with systemic manifestations, factors influencing the outcome of patients with pSS need to be…Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…Abstract Number: 0303 • ACR Convergence 2021
Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disease which is mostly characterized by the presence of xerophthalmia and xerostomia, caused by the lymphoplasmacytic…Abstract Number: 0319 • ACR Convergence 2021
Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disease associated with diverse phenotypes, which may include systemic disease activity. In real-world practice, the clinical presentation…Abstract Number: 1908 • ACR Convergence 2021
Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (SS), an autoimmune exocrinopathy, is expressed either as a local disease or as a systemic illness with an enhanced risk for…Abstract Number: 0304 • ACR Convergence 2021
Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
Background/Purpose: Renal disease in primary Sjogren's syndrome (pSS) can occur in form of tubulointerstitial nephritis (TIN) or glomerulonephritis (GN). Data from India on pSS is…Abstract Number: 0320 • ACR Convergence 2021
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…